(Q83575095)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22391455%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

title

Proteinuria as a surrogate end point--more data are needed (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22391455%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Aliza Thompson

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22391455%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

6 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22391455%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Nephrology

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22391455%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22391455%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22391455%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

306-309

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22391455%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrneph.2012.43

25 January 2020

exact match

0 references

cites work

Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

Are surrogate markers adequate to assess cardiovascular disease drugs?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

Surrogate end points in clinical trials: are we being misled?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

Surrogate endpoints in clinical trials: definition and operational criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

Blood pressure as an example of a biomarker that functions as a surrogate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

The normal hematocrit study--follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

Correction of anemia with epoetin alfa in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

Enrichment of clinical study populations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.43

31 March 2020

Identifiers

DOI

10.1038/NRNEPH.2012.43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22391455%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference